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Abstract
Innate immune sensing of viral molecular patterns is essential for development of antiviral 
responses. Like many viruses, SARS-CoV-2 has evolved strategies to circumvent innate 
immune detection including low CpG levels in the genome, glycosylation to shield essential 
elements including the receptor binding domain, RNA shielding and generation of viral 
proteins that actively impede anti-viral interferon responses. Together these strategies allow 
widespread infection and increased viral load. Despite the efforts of immune subversion, 
SARS-CoV-2 infection activates innate immune pathways inducing a robust type I/III 
interferon response, production of proinflammatory cytokines, and recruitment of neutrophils 
and myeloid cells. This may induce hyperinflammation or alternatively, effectively recruit 
adaptive immune responses that help clear the infection and prevent reinfection. The 
dysregulation of the renin-angiotensin system due to downregulation of angiotensin 
converting enzyme 2, the receptor for SARS-CoV-2, together with the activation of type I/III 
interferon response, and inflammasome response converge to promote free radical 
production and oxidative stress. This exacerbates tissue damage in the respiratory system 
but also leads to widespread activation of coagulation pathways leading to thrombosis. Here, 
we review the current knowledge of the role of the innate immune response following SARS-
CoV-2 infection, much of which is based on the knowledge from SARS-CoV and other 
coronaviruses. Understanding how the virus subverts the initial immune response and how an 
aberrant innate immune response contributes to the respiratory and vascular damage in 
COVID-19 may help explain factors that contribute to the variety of clinical manifestations 
and outcome of SARS-CoV-2 infection.
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Middle East respiratory syndrome coronavirus; MAV - mitochondrial antiviral signalling 
protein; N - nucleocapsid; NET - neutrophil extracellular trap;  NKB - nuclear factor kappa-
light-chain-enhancer of activated B cells; NLR - Nod-like receptor; NLRP3 - Nod pyrin 
domain-containing 3; ORF - open reading frame; PAMPs - pathogen-associated molecular 
patterns; PERK -  PRKR-like endoplasmic reticulum kinase; PLPro - papain like protease; PPR 
- pattern recognition receptors; RAGE – receptor for advanced glycation end products; RBD - 
receptor-binding domain; RIG-1 - retinoic acid-inducible gene I; RLR - retinoic acid-like 
receptors; RTC - replicase–transcriptase complex; SARS-CoV - Severe acute respiratory 
syndrome coronavirus; SARS-CoV-2 - severe acute respiratory syndrome coronavirus 2, STAT 
- signal transducer and activator of transcription; STING - stimulator of interferon genes; 
TBK-1 - TANK-binding kinase-1; TLR - Toll-like receptors;  UPR - unfolded protein response; 
URTI - upper respiratory tract infection; vWF - von Willebrand factor; ZAP - zinc finger 
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Introduction 
The emergence in Wuhan China of a novel severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) triggered an epidemic of the coronavirus disease 2019 (COVID-19). As of 
September 9th 2020, the confirmed 27,761,748 cases including 902,306 deaths have been 
reported worldwide (worldometers.info/coronavirus). At the end of January 2020, the WHO 
declared COVID-19 a pandemic and a global health emergency. 
The family Coronaviridae is subdivided into Torovirinae and Coronavirinae that contains the 
genera Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus. The 
human coronaviruses (HCoV) belong to the αlpha-CoV (HCoV-229E and HCoV-NL63) and 
beta-CoV (Middle East respiratory syndrome coronavirus-MERS-CoV, SARS-CoV, HCoV-OC43 
and HCoV-HKU1) [Table 1;(1–11)]. In comparison with most HCoVs that cause mild upper 
respiratory tract infections, SARS-CoV, MERS-CoV and SARS-CoV-2 induce severe pneumonia 
(12). The clinical presentation of COVID-19 ranges from mild ‘flu-like’ symptoms to severe 
respiratory failure and death although between 17.9-57% of SARS-CoV-2 infections are 
asymptomatic depending on the population (13). Common symptoms include fever, cough, 
fatigue, shortness of breath, headache and pneumonia. In addition, some patients develop 
gastrointestinal problems (14), and neurological manifestations, including headache, 
dizziness, hyposmia and hypogeusia. Age and comorbidities i.e., hypertension, chronic 
obstructive pulmonary disease, diabetes, obesity and cardiovascular disease predispose to 
more severe manifestations, including severe respiratory failure, septic shock, coagulation 
dysfunction, strokes, cardiovascular problems (15) and neurological manifestations (16). 
Although the origin and transmission of SARS-CoV-2 is unclear, genome sequencing reveals 
marked similarities with SARS-CoV (17). However, in comparison, SARS-CoV-2 spreads more 
quickly than SARS-CoV, likely due to the 10-20% fold higher in infectivity and transmissibility 
during the initial non-symptomatic period (4-5 days). In some cases, transmission has been 
reported after development of initial symptoms despite the presence of antibodies, (18) 
indicating that both, neutralising antibodies and T cell responses, are necessary to prevent 
reinfection and for protection (19). This is further supported by studies showing PD1+CD57+ T 
cell exhaustion, depletion or inactivation is associated with viral persistence in severe cases 
(20).
SARS-CoV-2 is a positive-sense RNA (29,903 nucleotides) enveloped virus of 60 to 140 nm 
diameter (21). The envelope is studded with homotrimers spike proteins of 8-12 nm length 
that are heavily decorated with N-glycans [figure 1 (22,23)]. Similar to other HCoVs, SARS-
CoV-2 genome encodes for four structural proteins: the spike (S), membrane (M), envelope 
(E) and the nucleocapsid (N) protein. The 5’ end of the genome is comprised of ORFa/ab, 
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non-structural proteins (nsp) while ORFs 2-10 encode the viral structural proteins - spike, 
envelope, membrane and nucleocapsid, and the accessory proteins [figure 1b]. Differences 
between the structural, non-structural and accessory proteins of SARS-CoV-2 and other 
coronaviruses help to explain the high infectivity rate and the range of pathologies observed 
(12,15,16). While knowledge of SARS-CoV2 is rapidly emerging, parallels with SARS-CoV, as 
well as ongoing sequencing data and antigenic typing will be crucial to understand the 
dynamics of the pandemic. SARS-CoV-2 cell entry is similar to SARS-CoV being mediated by 
the binding of the receptor-binding domain (RBD) of the S1 protein, to the angiotensin-
converting enzyme-2 (ACE-2), although other receptors such as CD147 and CD-SIGN have 
been reported [Table 1]. Docking of the RBD to the receptor and the action of furin, a serine 
protease that separates the S1 and S2 proteins exposes a second binding domain on S2 
allowing membrane fusion. Binding of the S protein to ACE-2 requires priming by cell 
proteases - primarily TMPRSS2, however, TMPRSS2 is expressed by a subset of ACE2+ cells 
supporting the notion that the virus likely uses other host enzymes such as TMPRSS4, 
lysosomal cathepsins and neuropilin-1 (24) to augment the impact of furin and expose the 
RDB thus promoting SARS-CoV-2 entry (11). The structural proteins M, E and N are crucial 
for stability of the viral genome and viral replication. The nsp and accessory proteins (25) 
encoded by 10 open reading frames (ORFs) have differing functions during viral replication 
[Table 2 (26-63] and many also act to deviate the innate immune response thus augmenting 
viral replication and spread. The degree to which the innate immune system is suppressed 
and evaded clearly determines the viral load and the host’s outcome to infection, the clinical 
symptoms and the severity of the disease. 
Evading Pattern Recognition Receptors 
Following infection, viral RNA is sensed by several classes of pattern recognition receptors 
(PPRs). The retinoic acid-like receptors (RLRs) include retinoid inducible gene I (RIG-I) and 
melanoma differentiation-associated gene 5 (MDA5), Toll-like receptors (TLR) – classically 3, 
7 and 8 that trigger IFN pathways and cytokines production [figure 2]. Once engaged these 
PPRs act downstream via the kinases TANK-binding kinase-1 (TBK1) and inhibitor-B kinases 
(IKKs). Such triggering leads to the activation of the transcription factors interferon-
regulatory factor-3 (IRF3) and 7 (IRF7) and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFB). These subsequently induce expression of type I IFNs (IFNα/β) and 
interferon stimulated genes (ISGs) [figure 2] many of which have potent antiviral activities, 
as well as other proinflammatory mediators e.g. cytokines, chemokines and antimicrobial 
peptides that are essential to initiate the host innate and adaptive immune response. In 
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trigger the inflammasome and IL-1 and IL-18 production leading to pyroptosis [figure 2]. 
Other PPRs and downstream factors relevant to SARS-CoV infection subversion of innate 
immune responses include C-type lectins and the stimulator of interferon genes (STING). 
While the cGas/STING pathway is commonly associated with sensing cytosolic DNA, it is also 
activated following binding of enveloped viruses to host cells and cytosolic viral RNA (64,65). 
Similar to TLRs and RLR, downstream, STING engages TBK1 to active IRF3 and/or NFB 
inducing type I IFN and/or proinflammatory cytokines [figure 2]. 
Coronaviruses have evolved several strategies to escape such innate immune recognition 
allowing widespread replication. Such evasion includes evolution of low genomic CpG, RNA 
shielding, masking of potential key antigenic epitopes as well as inhibition of steps in the 
interferon type I/III pathways. Generally, the zinc finger antiviral protein (ZAP) specifically 
binds to and degrades CpG motifs in genomes of RNA viruses. In comparison with other 
viruses, SARS-CoV-2 has evolved the most extreme CpG deficiency of all betacoronavirus 
[Table 2, (26)] thereby evading ZAP action. This suggests that SARS-CoV-2 may have 
evolved under selective pressure in either a new host or tissues expressing high levels of ZAP 
(26). Another strategy to protect mRNA used by the host and many viruses is the processing 
of capping the 5′ end. For both host and virus RNA, capping limits degradation and 
importantly blocks recognition by cytosolic PPRs. Like many RNA viruses SARS-CoV-2 has 
exploited several mechanisms to protect the 5′ ends by a cap structure of RNA generated 
during replication. While some viruses snatch the caps from host RNA, SARS-CoV-2, like 
other coronaviruses uses its own capping machinery composed of nsp10, nsp13 and the 
dedicated enzyme nsp16 to generate 2′-O-methyltransferase caps [suppl figure 1, (41)]. 
SARS-CoV-2 yields RNA caps indistinguishable from cellular mRNAs caps thereby evading 
detection by MDA5 and IFIT activity that target RNA for degradation [figure 2]. The 
importance of such capping and viral replication is supported by studies of SARS-CoV in mice 
lacking 2′-O-MTase activity underscoring that MDA5 and the IFIT family are critical for IFN 
signalling (45). While counter-intuitive, SARS-CoV uses its endoribonuclease (nsp15) to 
cleave its own viral RNA in the cytosol that would otherwise act as PAMPs thus evading 
MDA5, protein kinase R (PKR), and OAS/RNAse L (44,66). Yet another strategy used by 
SARS-CoV-2 to protect the viral RNA and proteins generated during replication [suppl figure 
1] is the use of replicase–transcriptase complex (RTC) or replication organelle, formed of 
double-membrane vesicles (33). The RTCs link with the ER-Golgi intermediate compartment 
(ERGIC) and Golgi apparatus shielding the virus during maturation [suppl figure 1]. Another 
immune evasion strategy utilized by coronaviruses is the use of glycans and likely other post 
translational modifications to mask immunogenic viral protein epitopes [figure 1C and D]. The 
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proteins of 8-12 nm length that are heavily decorated with glycans. Each spike protein 
comprises of two subunits (S1 and S2) that each bear 22 glycan groups (49). Cell entry of 
the highly glycosylated S protein of SARS-CoV is promoted by DC-SIGN possibly augmenting 
virus uptake or aiding capture and transmission of SARS-CoV by DCs and macrophages (6-8). 
Similar to the spike protein, the other structural, non-structural and accessory proteins are 
also modified by glycosylation, palmitoylation, phosphorylation, SUMOylation and ADP-
ribosylation (67). Conversely, some viral proteins e.g. nsp3, possess deubiquitinating (DUB) 
and deISGylation activity thereby interfering with host functions targetting those that are 
critical for signalling transduction of innate immunity (34). Insertion of the spike protein into 
cell membranes during replication is a key step for virus budding. Whilst this takes place in 
the RTC [suppl figure 1], receptor-bound spike proteins interact with TMPRSS2 expressed on 
the uninfected cell surface, mediates fusion between infected and uninfected cells promoting 
the formation of syncytia allowing the virus to spread to adjacent uninfected cells while 
evading detection by the immune response (68). 
SARS-CoV-2 subversion of innate immune responses 
In addition to strategies to evade PPR recognition, SARS-CoV-2 has also evolved strategies to 
inhibit steps in the pathway leading to type I/III IFN production. This may be especially 
relevant in the lungs where type IFN III (lambda) is considered to be more effective in 
controlling viral infections and critically affected in COVID-19. Knowledge arising from the 
study of other coronaviruses, especially SARS-CoV and MERS, has shown that many of the 
non-structural, structural and accessory proteins interfere with elements of the IFN pathway 
[Table 2, figure 2], essential for the development of effective immunity. IFN antagonism has 
been attributed to several of the structural, non-structural and accessory proteins that 
interfere with stimulator of interferon genes (STING)-TRAF3-TBK1 complex, thereby blocking 
STING/TBK1/IKKε-induced type I IFN production, STAT-1/2 translocation to the nucleus, 
IRF3, NFB signalling as well as interfering with the actions of the ISG products including 
IFITs [Table 2]. As examples, nsp1, 4 and 6, and ORF6 interfere with STAT-1/2 signalling 
while nsp 10, 13 and 16 cap the viral RNA [Table 2] preventing recognition by RIG-I, MDA5 
and IFITs. Nsp3 also acts by DUB proteins thereby preventing their activity such as RIG-I and 
other steps in the IFN pathways for which ubiquitination is essential. CoV PLPro (nsp 3) also 
interrupts the stimulator of interferon genes STING.TRAF3. TBK1 complex thereby blocking 
STING/TBK1/IKKε-type I IFN production (32,34). As well as subversion of the IFN pathway, 
SARS-CoV ORF7a (also present in SARS-CoV-2) blocks the activity of tetherin also known as 
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cell membrane thus preventing its release from the cells. ORF7a removes this inhibition 
aiding the release of mature virions. 
In summary, emerging evidence from SARS-CoV-2, and comparison with other SARS-Cov 
and MERS, reveals many strategies used to evade the innate immune response and subvert 
the interferon pathway. While this facilitates widespread viral replication increasing the viral 
load also promotes the viral cytopathic effects leading to tissue damage described below, 
likely leads to exacerbation and hyperinflammation of the innate immune response once 
triggered.   
Triggering Innate Immunity
Despite immune evasion and subverting innate immune responses during early infection, 
SARS-CoV-2 effectively initiates immune signalling pathways. This is likely due to the 
increased viral load that exponentially produces viral RNA and viral proteins (pathogen 
associated molecular patterns – PAMPS), also induces cell damage that release damage 
associated molecular patterns (DAMPS) both of which trigger innate immune pathways. 
Like SARS-CoV and NL63, SARS-CoV-2 uses the angiotensin (Ang)-converting enzyme-
2 (ACE2) as a cell receptor [Table 1], expressed on epithelia in renal, cardiovascular and 
gastrointestinal tract tissues, testes and on pneumocytes and vascular endothelia (66). ACE2 
regulates the renin-angiotensin system (RAS) by balancing the conversion of angiotensin I to 
angiotensin 1–9 and angiotensin II to angiotensin 1–7. Binding of SARS-CoV-2 to ACE2 leads 
to endosome formation, reducing ACE2 expression on the cell surface [figures 3 and 4] and 
pushing the RAS system to a pro-inflammatory mode triggering production of reactive oxygen 
species, fibrosis, collagen deposition and a proinflammatory environment including IL-6 and 
IL-8 production by macrophages and recruitment of neutrophils [figure 4]. Thus, binding and 
entry of SARS-CoV-2 via the ACE2 is likely to be the first step in a line of augmented and 
detrimental immune responses in COVID-19 that involves complement activation, innate 
immune activation via PAMPS and DAMPS, inflammasome activation and pyroptosis, NK cell 
activation, hyperactivation of macrophages, neutrophils and innate T cells and induction of a 
cytokine storm as discussed below. 
Complement
SARS-CoV-2 is heavily decorated with glycans [figure 1] that are recognised by DC-SIGN and 
other lectins that facilitate viral uptake by dendritic cells. Glycans also activate the lectin 
complement pathway following binding of mannose binding protein (MBP) to SARS-CoV-2 
viral proteins expressed on infected cells [figures 1 and 2]. Pathology studies and 
transcriptional profiles of tissues from COVID-19 cases reveal robust activation of the 
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attack complex (MAC) in alveolar and epithelial cells (68,69) [figure 4]. In addition, C4d and 
C5b-9 deposits in lung and skin microvasculature co-localised with spike glycoproteins 
indicates systemic complement activation, supporting the role of complement in tissue 
damage (68). Importantly, activation of the lectin, as well as the classical pathway following 
antibody binding to viral proteins, likely contributes to cell damage [figure 4, (70)] by either 
direct complement mediated lysis or via antibody dependent cell mediated cytotoxicity. Of 
relevance to the coagulation dysfunction, thrombosis and vascular damage observed 
following SARS-CoV-2 infection is that complement components induce secretion of von 
Willebrand factor (71) but also promotes monocyte and neutrophil recruitment as well as 
stimulates NET formation (72) that in turn perpetuates complement activation [figure 4]. 
Complement may thus contribute to widespread tissue damage in SARS-CoV-2 infected 
cases. The pathogenic role of complement in disease is supported by findings in mice. For 
example, mice deficient in C3 had similar viral load as wildtype mice but lacked the overt 
pathology with fewer neutrophils and macrophages in the lung (73). Thus, while complement 
activation is not required for control of virus infection it likely plays a key role in the tissue 
damage.
PAMPS and DAMPS mediate innate immune signalling
Infected pneumocytes and other permissible cells undergo cell damage and cell death 
releasing virally-associated molecules so-called ‘pathogen associated molecular patterns’ 
(PAMPS). In addition, intracellular components released due to damage so-called ‘damage or 
danger associated molecular patterns’ (DAMPS) include ATP, oxidized lipids, heat shock 
proteins and other components associated with regulated cell death programmes including 
apoptosis, autophagy, necroptosis, and pyroptosis [figure 3 and 4]. Thus, both DAMPS and 
PAMPS contribute to innate immune activation in COVID-19.
RNA viruses trigger several TLRs, including TLR7/8 and TLR3, and elegant molecular in silco 
docking studies show that the spike protein of SARS‐CoV‐2 can bind to TLR1, TLR4, and 
TLR6 (74) (figure 3) whereas in vitro the SARS-CoV spike protein triggers NFB activation 
and IL-8 production via TLR2 signalling in human peripheral blood mononuclear cells (75). In 
mice in which specific points in the TLR pathway were deleted i.e. TLR3−/−, TLR4−/−, and 
TRAM−/−, animals were more susceptible to SARS-CoV infection, although the clinical severity 
of disease was dramatically reduced. This was in direct contrast to deficiency in TRIF, the TLR 
adaptor protein [figure 3] in which TRIF-/- mice developed severe disease, exacerbated influx 
of macrophages and neutrophils, and lung pathology indicative of COVID-19 pathology. Thus, 
a balanced response to infection via TLR3 pathway is essential to trigger a protective 









This article is protected by copyright. All rights reserved
immune pathways triggered by DAMPS such as oxidised phospholipids, high mobility group 
box 1 (HMGB1), histones, heat shock proteins and adenosine triphosphate released by 
damaged cells may contribute to COVID-19 outcome [figures 3 and 4]. In addition to RIG-I, 
MDA5 and MAVS, RNA viruses are also sensed by the stimulator of interferon genes (STING) 
that is activated by cGAMP when enveloped RNA viruses interact with the host membranes 
(64). Downstream, STING engages TBK1 that actives IRF3 and/or NFB inducing type 1 IFN 
and/or proinflammatory cytokines. That hyperactivation of STING contributes to severe 
COVID-19 as has been hypothesised by Berthelot and Lioté (77). These authors present 
several lines of evidence, the strongest being that gain of function mutations of STING 
associated with hyperactivation of type I IFN induces the disease SAVI (STING-Associated 
Vasculopathy with onset in Infancy). Affected children with SAVI present with pulmonary 
inflammation, vasculitis and endothelial-cell dysfunction that mimics many aspects of COVID-
19 (78). Furthermore, STING polymorphisms are associated with ageing-related diseases 
such as obesity and cardiovascular disease, possibility explaining the impact of comorbidities 
and development of severe COVID-19 (78). Also, in bats in which SARS-CoV-2 may have 
arisen, STING activation and thus consequently IFN is blunted (79), likely aiding viral 
replication and spread as observed in early SARS-CoV-2 infection in humans. That DAMPS 
released due to viral cytotoxicity may contribute to severe COVID-19 which is best 
exemplified by HMBG1 released by damaged and dying cells as well as activated innate 
immune cells especially in sepsis (80). Depending on its conformation HMGB1 triggers TLR2, 
TLR4 and TLR9, the receptor for advanced glycation end-products (RAGE) and triggering 
receptor expressed in myeloid cells 1 (TREM-1) [figure 3]. In mice, intratracheal 
administration of HMGB1 activates mitogen-activated protein kinase (MAPK) and NFκB, 
inducing proinflammatory cytokines, activating the endothelium and recruiting neutrophils in 
the lung – key pathological features of severe COVID-19 (80,81). HMGB1, and especially the 
platelet-derived source may play a crucial role in SARS-CoV-2 vascular damage since HMGB1-
/- mice display delayed coagulation, reduced thrombus formation and platelet aggregation 
(82). Furthermore, blocking HMGB1 is beneficial in experimental lung injury and sepsis, 
suggesting therapies targeting HMGB1 might also be beneficial in severe COVID-19 (83). 
Inflammasome activation and pyroptosis
Studies of peripheral blood and post-mortem tissues from severe COVID-19 cases reveal high 
levels of IL-1β and IL-6 and increased numbers of CD14+IL-1β monocytes, suggesting 
activation of the Nod-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome 
pathway (84). Activation of the NLRP3 inflammasome, essential for effective antiviral immune 
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disbalance, engagement of PPR, TNFR and IFNAR, mitochondrial ROS production, 
complement components including MAC, as well as SARS-CoV viral proteins such as ORF3a, N 
and E [figure 3, Table 2]. As a consequence, NLRP3 interaction with adaptor apoptosis speck-
like protein (ASC) recruits and activates procaspase-1, processing pro-IL-1β and pro-IL-18 to 
the activate forms [figure 3]. This drives the propyroptotic factor gasdermin D (GSDMD) 
formation of pores in the cell membrane, i.e. pyroptosis that facilitates the release of 
proinflammatory cytokines. The pores also aid the release of cellular DAMPS such as HMGB1, 
and viral PAMPS that further exacerbate inflammation suggesting that targeting the NLRP3 
pathway might be beneficial in severe COVID-19 cases. 
Hyperinflammation and severe COVID-19 
The delayed interferon response, increased viral load and virus dissemination, coupled with 
the release of DAMPS and PAMPs lead to activation of several innate immune pathways. 
Following infection, pneumocytes, epithelial and alveolar cells, and infiltrating monocyte-
macrophages and neutrophils likely produce the first wave of TNFα, IL-6, IP-10, MCP-1, MIP-
1 and RANTES production (87,88). Hyperinflammation is likely promoted by comorbidities 
due to increased ACE2 expression, concurrent bacterial infections and ageing as well as a 
direct effect of SARS-CoV-2 replication since virus-host interactome studies reveal that SARS-
CoV-2 nsp10 regulates the NFB repressor factor NKRF, facilitating IL-8 production (89). This 
is followed by a second wave of cell recruitment including NK cells that produce IFN and 
further recruitment of (alternatively activated) monocytes/macrophages and neutrophils 
[figure 4] as observed in bronchial lavages, post-mortem tissues and peripheral blood studies 
(88,89). NK cells are key players in disease outcome of infection, critically balancing the 
direct response to the virus by eliminating infected cells while also augmenting tissue damage 
[figure 4]. Likely aided by IFN induction by NK cells, hyperinflammation in severe COVID-19 
is also characterised by recruitment of immature and mature human monocyte-derived DCs 
that harbour SARS-CoV infection, however, infection is abortive and mature virions are not 
released. During infection, DCs express only low levels of cytokines likely due to innate 
immune subversion strategies. The sustained activation of infiltrating monocytes and 
monocyte-derived macrophages (90) observed in severe COVID-19 cases is likely driven by a 
number of factors including oxidative stress, anti-SARS-CoV-2 antibody:antigen complexes, 
NLRP3 inflammasome activation, and complement activation that converge to sustain an 
aberrant hyperinflammatory response, or cytokine storm (91). Following SARS-CoV-2 
infection, one of the first innate immune cells to infiltrate into the tissues are neutrophils, 
likely recruited by CXCL2 and CXCL8 generated by infected cells (92). While neutrophils do 
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releasing proteolytic enzymes, antimicrobial peptides, matrix metalloproteinases and high 
levels of ROS to inactivate viruses. A key function of neutrophils relevant to the pathology of 
SARS-CoV-2 is the production of neutrophil extracellular traps (NETs) generated in response 
to endothelial damage, ROS production, IL-1 production and virus replication [figure 4, 
reviewed in (93)]. The formation of NETs by neutrophils are aided by activated platelets 
associated with damaged endothelial cells that further activate the complement, fuelling the 
coagulation cascade and thrombi formation. While the NETs act to prevent further spread of 
the virus they trigger platelet activation and bind erythrocytes thereby promoting 
(micro)thrombi formation [figure 4]. 
SARS-CoV-2 is a vascular and coagulation disease
While respiratory damage and complications are the major clinical signs of severe COVID-19 
many tissues and organs are affected often prior to, or independently of lung pathology, for 
example Kawasaki-like vascular disease in children (94). Clinical, post-mortem studies and 
experimental animal models of SARS-CoV reveal infection of endothelial cells and the 
widespread damage of endothelial cells, vascular dysfunction and thrombosis (94,95) that are 
emerging as a common pathological feature of SARS-CoV-2 infection. The link between 
SARS-CoV-2 infection, vascular damage and thrombosis is evidenced by high levels of D-
dimers in 20-40% critically ill patients likely produced in an attempt to dissolve thrombotic 
clots. The endothelial cell damage is supported by the finding that endothelial cells express 
ACE2 and are thus permissible to SARS-CoV-2 infection (94). Thus, infection not only leads to 
reduced ACE2 in endothelial cells, but also direct viral cytopathic damage and increased 
vascular permeability [figure 4], although more recent data challenge this view suggesting 
that pericytes and not endothelial cells are permissible to infection and viral induced damage 
(95,96). Damage of endothelial cells and pericytes leads to vascular permeability in severe 
COVID-19 that is likely amplified by activation of complement components widely expressed 
in post-mortem tissues of COVID-19 cases (68,69). Disruption of the vascular barrier and 
endothelial cell exposure to IL-1, TNF and ROS increase expression of P-selectin, von 
Willebrand factor (vWF) and fibrinogen, and attracting platelets that trigger expression of 
tissue factor [figure 4]. Together, this sequence triggers the coagulation cascade and explains 
the finding of increased D-dimer and fibrin, abnormal clotting times in severe COVID-19 
cases and widespread disseminated thrombi in post-mortem tissues. 
Disease severity, comorbidities and innate immunity 
SARS-CoV-2 exploits many strategies to subvert innate immune responses allowing the virus 
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the host, and the efficacy of the host innate immune response to eradicate the infection and 
trigger effective adaptive immune responses, but not hyper-responsiveness of innate 
immunity, strongly determines the disease outcome [Table 3]. The severity of infection has 
been linked to age, smoking, comorbidities such as cancer, immune suppression, 
autoimmune diseases, inflammatory disease, neurodegenerative diseases, obesity, gender 
and race (97–106). For example, in a large cohort of 72,314 cases the case fatality ratio for 
over 80 years was 14.8% versus 2.3% in the total cohort (97). This is likely higher due to 
inflamm-ageing, an aberrant innate immune response such as lower production of IFNβ (98), 
increased oxidative stress (99) and sensence of macrophages that become less effective in 
their reparative functions with age (100). Likewise, viral load, obesity, gender, race, blood 
groups and comorbidities have all been reported to influence the response to SARS-CoV-2 
infection, [Table 4; (101–112)] although few studies have fully examined the extent to which 
subversion and activation of innate immune components contribute to susceptibility in these 
cases. 
Future perspectives
Understanding the innate immune factors that exacerbate the vascular complications will be 
crucial to control severe disease following SARS-CoV-2 infection. Rapidly emerging studies 
reveal the extent to which therapeutic approaches for other viral infections and inflammatory 
diseases can be repurposed to target innate immunity to treat COVID-19 patients (113,114). 
Likewise, novel approaches have been put forward to target the susceptible ageing population 
or those with comorbidities. One approach under investigation is to re-establish the youthful 
function of macrophages and repair mechanisms using metformin, a drug used in type 2 
diabetes that has been shown to attenuate hallmarks of ageing (115). In a retrospective 
study of 25,326 subjects tested for COVID-19 while diabetes was reported to be an 
independent risk factor for COVID-19-related mortality (116) the risk in subjects taking 
metformin was significantly reduced (OR 0.33; 95%CI 0.13-0.84) suggesting metformin 
might be protective in high risk populations (ref) especially since metformin has also been 
reported to suppress neutrophil induced NETosis in vitro and reduce circulating NETosis 
biomarkers in vivo (117). Thus, metformin and other drugs such as niacin (118) that 
rejuvenate the innate immune system may be useful in COVID-19. 
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Table 1. HCoVs - cell receptors and cofactors aiding viral entry 















 APN (CD13) Renal and GI epithelia, 
synaptic membranes, 
pericytes, myeloid 





















ACE2 Respiratory, intestinal 
epithelial cells, 















cells, endothelial cells, 



















DPP4 (CD26) Intestinal, alveolar, 
renal, hepatic and 
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ACE 2 - angiotensin-converting enzyme 2; APN -  aminopeptidase N; DCs dendritic cells; DC-
SIGN – Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin 
(CD209), DC-SIGNR – DC-SIGN receptor; DPP4- dipeptidyl peptidase 4; GI - gastrointestinal; 
HLA-C – human leukocyte antigen C; IFIT - interferon-induced proteins with tetratricopeptide 
repeats; TMPRSS - type II transmembrane serine proteases, URTI – upper respiratory tract 
infection. 
Table 2. Immune evasions strategies of genome and encoded proteins of SARS-CoV 
and (by inference) SARS-Cov-2 





Decreased activity of ZAP 
and APOBEC3G.
ZAP expressed in 
immune cells.
(26)
ORF1a nsp1 Mediates RNA 
replication and 
processing. 
Involved in RNA 
degradation. 
Modulates calcineurin/ 
NFAT pathway. Cleaves 
host RNA. Inhibits 
cyclophilins and 
immunophilins. Blocks 
ATF2/c-Jun, IRF3 and 
IRF7, NFB, decreases 
STAT1 phosphorylation. 

















ACE2 Respiratory, intestinal 
epithelial cells, 
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pathway. 
nsp2 Replicase essential 
for proofreading 
replication. 
May bind to prohibitin 1 










growth and RNA 
synthesis.
(30,31)







deISGylates host proteins 
Blocks IFNa, IFNβ, 
CXCL10 and CCL5. 
Inhibits TLR7 signalling 














nsp4 Complexes with 
nsp3 and nsp6 to 
form the DMV. 
May anchor RTC to 
ER.
Helps replication process 






Induces apoptosis and 
growth arrest via 
caspase-3 and caspase-9.
(35)
nsp6 Complexes with 
nsp3 and nsp4 to 
form DMV.
Helps replication process 




nsp7 Complexes with 
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nsp8 Complexes with 













nsp10 Complexes with 




Interacts with the oxido-
reductase system causing 
cytopathic effect. 
Aids RNA capping thus 




Forms a complex 
with nsp16. 
(39-41)
nsp11 Peptide resulting 
from cleavage of 
pp1a at nsp10/11 
junction
Not known




limits host cellular 
responses
(36)
nsp13 helicase key for 
efficient 
replication of viral 
genome
Caps RNA thus evades 
RIG-I and MDA-5 
signalling 
Failure to trigger 
IFIT1.
(42)
nsp14 exon 3′–5′ 
exonuclease plays 
crucial role in viral 




Involved in the capping 
through its function as a 
guanine-N7 
methyltransferase 
helping nsp16 evade 







nsp15 uridylate -specific 
endoribonuclease 
(EndU) 
Limits exposure of viral 
dsRNA to the sensors 
MDA5, PKR, and 
OAS/RNaseL. Inhibits 
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MDA5 thus antagonizing 
IFN-a/ production.
nsp16 2’-O-ribose methyl 
transferase 




Caps RNA thus evades 
RIG-I and MDA-5 
signalling
Failure to trigger 
IFIT1
(41,45,46)










Induced misbalanced in 






ORF3a ORF3a Interact with 
SARS-CoV M, S, E, 
and 7a proteins
Forms viroporins
Activates PERK pathway, 
triggers apoptosis 
through expression of 
ATF4 and CHOP. 
Downregulates and 
degrades Type 1 IFNR.












Induces ROS and 
activates inflammasome
(53,54)
ORF5 Membrane Important for viral 
assembly
Inhibits type I interferon 
production by impeding 






ORF6 ORF6 Plays a role in 
viral pathogenesis, 
interacts with 
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viral virulence.
ORF7a ORF7a Interacts with S 
protein and p3a.
Not essential for 
replication 
Inhibits BST-2 
glycosylation, leading to 
a loss of function of BST-











ORF7b ORF7b Not essential for 
viral replication 
but structural 
component of the 
virion. 
It is an integral 
membrane 









encodes p8a and 














TRAF6 and antagonizes 
IFN-β 
(51,62,63)
ORF10 ORF10 Ubiquitin ligase unknown
ACE 2 - angiotensin-converting enzyme 2; BST - bone marrow stromal antigen 2; CHOP -  
C/EBP homologous protein;  DMV – double membrane vesicles; HCoV- human coronavirus;  
IFN – interferon; LFA - Lymphocyte function-associated antigen 1; MAV – mitochondrial 
antiviral signalling protein; MHC - major histocompatibility antigen;  ORF – open reading 
frame PERK -  PRKR-like endoplasmic reticulum kinase; RIG-1 -  retinoic acid-inducible gene 
I; ROS – reactive oxygen species; STAT -  signal transducer and activator of transcription; 
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NK cell and 
complement 
mediated clearance 




cytokine storm e.g. IL-6, 
IL-8, TNF, delayed or 
ineffective adaptive 




tissue damage due 
to inflammatory 
response









no not likely or mild highly likely and 
contributes to clinical 
disease and tissue 
damage hence the finding 
of high levels of D-dimer 
produced to counteract 
thrombi formation.
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>80 - 14.8% vf 2.3%
70-79 – 8.0%
Increased oxidative 





Blood groups Higher risk in blood 
group A and 
protective effect in 
blood group O in a 
cohort of 1,610 cases
Neutralizing antibodies 
against protein-linked N-
glycans on SARS-CoV-2, 








myocarditis, impact of 
drugs on RAS. Increase 
levels of vWF.
(97,104)
Cancer 4.7%, 5.6% unknown (97,105)
Diabetes 
mellitis
7.3% Reduced ACE2 levels in 
diabetes already 
predispose to a 
proinflammatory 
environment. Increased 
IL-6 levels. Increased 
levels of vWF
(97,106)
Gender Increased CFR for 
males across all ages
Differential expression 
levels of ACE2, hormonal 
regulation of immune 
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Ethnicity Higher risk in some 
ethnic groups not 
due to socioeconomic 
conditions
Difference in TLR 
expression, levels of IL-6 
and TNF.
Reduced levels of VitD. 
(109,110)
Obesity BMI >25 or 30 
increased risk of 
severe pneumonia by 
86% and 140% 
Dysregulated NK cells, 
increased numbers of 
myeloid cells in adipose 
tissues and expression of 
ACE2 by adipocytes
(111,112)
ACE 2 - angiotensin-converting enzyme 2; CFR- case fatality ratio; NK cells – natural killer 
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FIGURE LEGENDS
Figure 1. SARS-CoV-2 structure and genome.  A) SARS-CoV-2 is a positive-sense RNA 
enveloped virus with the spike (S), membrane (M), envelope (E) proteins embedded in the 
lipid envelope, while the nucleocapsid (N) protein is associated with the RNA. B) The 5’ end 
of the genome is comprised of ORFa/ab encoding 2 large polyproteins including the replicase 
protein crucial for self-generation of the non-structural proteins (nsp) while ORFs 2-10 
encode the viral structural proteins (S, M, E and N) and accessory proteins. C) The 
homotrimers spike proteins of 8-12 nm length are heavily decorated with N-glycans moieties 
that can be recognised by antibodies, C-type lectins and mannose binding proteins that aid 
viral attachment to permissible cells, activate the complement system and may be recognised 
by macrophages and antibodies (D). 
Figure 2. SARS-CoV-2 subversion of interferon pathways. SARS-CoV-2 infects 
permissible cells via the angiotensin converting enzyme two (ACE2). Following infection (A) 
the virion or viral RNA is sensed by either the cGas/STING pathway where stimulator of 
interferon genes (STING) engages TBK1, or via retinoid inducible gene I (RIG-I) and 
melanoma differentiation-associated gene 5 (MDA5). These pathways lead to activation of 
IRF3 and/or NFkB inducing type I/III IFN that is recognised by IFN receptors (B) and 
subsequent induction of the interferon stimulated genes (ISGs) and proteins many of which 
have potent antiviral activities. Based on the knowledge of other coronaviruses especially 
SARS-CoV, and emerging data from SARS-CoV-2 many of the non-structural, structural and 
accessory protein subvert and inhibit numerous steps in these pathways thereby inhibiting 
IFN production allowing increased viral replication.  
Figure 3. SARS-CoV-2 activates innate immune pathways.  SARS-CoV-2 infects 
permissible cells via the angiotensin converting enzyme two (ACE2) and is taken by in the 
endosome where the virus is recognised by Toll-like receptor 7/9 triggering MyD88 pathway, 
or TLR 3 via the TRIF pathway (A). PAMPS and DAMPS are also recognised by TLR4 (B) or 
RAGE (D) triggering HMGB1induced damage and NLRP3 inflammasome activation. During 
viral replication ORF3a and E proteins form viroporins that augment ROS production and 
inflammasome activation. 
Figure 4. SARS-CoV-2 is a vascular and coagulation disease. A) Binding of SARS-CoV-2 
to ACE2 blocks ACE2-induced formation of antioxidant angiotensin, facilitating oxygen free-
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(B) and hyperinflammation with influx of macrophages, NK cells and neutrophils (C). This 
self-augmenting cycle triggers further cell damage and DAMPS and PAMPs release as well as 
ROS production. D) Activation of neutrophils induces neutrophil extracellular traps (NET) 
aided by the N protein and generated in response to ROS-induced endothelial cell damage. 
Disruption of the vascular barrier and endothelial cell exposure to proinflammatory cytokine 
and ROS increases expression of P-selectin, von Willebrand factor (vWF) and fibrinogen, that 
attract platelets triggering expression of tissue factor. Together this sequence activates the 
complement system, one of many pathways that crucially activates the coagulation cascade 





















































































NET formation promotes 
endothelial cell damage, leaky 
blood vessels and thrombosis 
NET
